{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:23Z","timestamp":1792522943020,"version":"4.5.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0231999","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T17:25:01Z","timestamp":1588785901000},"page":"e0231999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8772-7891","authenticated-orcid":true,"given":"Jacob","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Hartmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"Trabucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-2750","authenticated-orcid":true,"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-1783","authenticated-orcid":true,"given":"Lee A.","family":"Albacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-7105","authenticated-orcid":true,"given":"Anneleen","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"pone.0231999.ref001","volume-title":"Global cancer in women: burden and trends","author":"L. A. Torre","year":"2017"},{"key":"pone.0231999.ref002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"G. P. Gupta","year":"2006","journal-title":"Cell"},{"key":"pone.0231999.ref003","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"S. Valastyan","year":"2011","journal-title":"Cell"},{"key":"pone.0231999.ref004","first-page":"311","article-title":"Breast cancer metastasis","volume":"9","author":"O. J. Scully","year":"2012","journal-title":"Cancer Genomics-Proteomics"},{"key":"pone.0231999.ref005","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-46356-8","volume-title":"Management of Breast Diseases","author":"I. Jatoi","year":"2016"},{"key":"pone.0231999.ref006","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/cncr.27819","article-title":"Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy","volume":"119","author":"A. J. Tevaarwerk","year":"2013","journal-title":"Cancer"},{"key":"pone.0231999.ref007","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"P. S. Steeg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"pone.0231999.ref008","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2014.55.4139","article-title":"Past, present, and future challenges in breast cancer treatment","volume":"32","author":"G. W. Sledge","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"pone.0231999.ref009","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"E. B. C. T. C. Group","year":"2005","journal-title":"The Lancet"},{"key":"pone.0231999.ref010","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"I. E. Smith","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"pone.0231999.ref011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"A. Howell","year":"2005","journal-title":"Lancet"},{"key":"pone.0231999.ref012","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"E. H. Romond","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"pone.0231999.ref013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"I. Smith","year":"2007","journal-title":"The lancet"},{"key":"pone.0231999.ref014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors","volume":"490","author":"C. G. A. Network","year":"2012","journal-title":"Nature"},{"key":"pone.0231999.ref015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"G. Ciriello","year":"2015","journal-title":"Cell"},{"key":"pone.0231999.ref016","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","author":"M. D. Burstein","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"pone.0231999.ref017","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"B. Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"pone.0231999.ref018","unstructured":"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA\/AKT1\/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03337724. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref019","unstructured":"AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03310541. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref020","unstructured":"Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4\/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03056755. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref021","unstructured":"Fulvestrant, Palbociclib and Erdafitinib in ER+\/HER2-\/FGFR-amplified Metastatic Breast Cancer\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03238196. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref022","unstructured":"Pembrolizumab in Advanced BRCA-mutated Breast Cancer\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03025035. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref023","unstructured":"PARP Inhibition for Triple Negative Breast Cancer (ER-\/PR-\/HER2-)With BRCA1\/2 Mutations\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01074970. (Accessed: 13th November 2017)"},{"key":"pone.0231999.ref024","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"D. R. Robinson","year":"2013","journal-title":"Nat. Genet"},{"key":"pone.0231999.ref025","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"S. Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"key":"pone.0231999.ref026","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"G. Schiavon","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"pone.0231999.ref027","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11579","article-title":"Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant","volume":"7","author":"J. M. Spoerke","year":"2016","journal-title":"Nat. Commun"},{"key":"pone.0231999.ref028","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","author":"A. Zehir","year":"2017","journal-title":"Nat. Med"},{"key":"pone.0231999.ref029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic evolution of breast cancer metastasis and relapse","volume":"32","author":"L. R. Yates","year":"2017","journal-title":"Cancer Cell"},{"key":"pone.0231999.ref030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"P. Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"pone.0231999.ref031","author":"Lindsay Angus","year":"2018","journal-title":"The genomic landscape of 501 metastatic breast cancer patients"},{"key":"pone.0231999.ref032","author":"Fabrice Andre","year":"2018","journal-title":"Genomic characterization of metastatic breast cancer"},{"key":"pone.0231999.ref033","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"G. M. Frampton","year":"2013","journal-title":"Nat. Biotechnol"},{"key":"pone.0231999.ref034","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"J. He","year":"2016","journal-title":"Blood"},{"key":"pone.0231999.ref035","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"S. A. Forbes","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"pone.0231999.ref036","unstructured":"Ho, T. K. Random decision forests. in Document Analysis and Recognition, 1995., Proceedings of the Third International Conference on 1, 278\u2013282 (IEEE, 1995)."},{"key":"pone.0231999.ref037","volume-title":"R: a language and environment for statistical computing. Version 3.1. 3","author":"R. C. Team","year":"2015"},{"key":"pone.0231999.ref038","first-page":"1","article-title":"Caret package","volume":"28","author":"M. Kuhn","year":"2008","journal-title":"J. Stat. Softw"},{"key":"pone.0231999.ref039","first-page":"18","article-title":"Classification and regression by randomForest","volume":"2","author":"A. Liaw","year":"2002","journal-title":"R News"},{"key":"pone.0231999.ref040","doi-asserted-by":"crossref","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"J. X. Sun","year":"2018","journal-title":"PLoS Comput. Biol"},{"key":"pone.0231999.ref041","doi-asserted-by":"crossref","first-page":"e0160519","DOI":"10.1371\/journal.pone.0160519","article-title":"Lollipops in the clinic: information dense mutation plots for precision medicine","volume":"11","author":"J. J. Jay","year":"2016","journal-title":"PloS One"},{"key":"pone.0231999.ref042","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H. Wickham","year":"2016"},{"key":"pone.0231999.ref043","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Z. Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"pone.0231999.ref044","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"H. Kennecke","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"pone.0231999.ref045","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.bjc.6690628","article-title":"Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis","volume":"80","author":"P. D. P. Pharoah","year":"1999","journal-title":"Br. J. Cancer"},{"key":"pone.0231999.ref046","first-page":"2016","article-title":"High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis","volume":"2479","author":"R. J. Hartmaier","year":"2017","journal-title":"Cancer Res. canres"},{"key":"pone.0231999.ref047","doi-asserted-by":"crossref","first-page":"e1002201","DOI":"10.1371\/journal.pmed.1002201","article-title":"Mutational profile of metastatic breast cancers: a retrospective analysis","volume":"13","author":"C. Lefebvre","year":"2016","journal-title":"PLoS Med"},{"key":"pone.0231999.ref048","first-page":"279","article-title":"An update on the genomic landscape of breast cancer: new opportunity for personalized therapy?","volume":"1","author":"A. Daemen","year":"2012","journal-title":"Transl. Cancer Res."},{"key":"pone.0231999.ref049","first-page":"48","article-title":"Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity","volume":"62","author":"G. N. Filippova","year":"2002","journal-title":"Cancer Res"},{"key":"pone.0231999.ref050","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ng.3335","article-title":"CTCF\/cohesin-binding sites are frequently mutated in cancer","volume":"47","author":"R. Katainen","year":"2015","journal-title":"Nat. Genet"},{"key":"pone.0231999.ref051","doi-asserted-by":"crossref","first-page":"593.8","DOI":"10.1096\/fasebj.31.1_supplement.593.8","article-title":"The role of CCCTC binding factor (CTCF) in epithelial to mesenchymal transition (EMT)","volume":"31","author":"A. Bhattacharya","year":"2017","journal-title":"FASEB J"},{"key":"pone.0231999.ref052","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"I. M. Chu","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"pone.0231999.ref053","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"R. S. Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"pone.0231999.ref054","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"T. Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"pone.0231999.ref055","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ijc.26304","article-title":"Mechanisms of FGFR3 actions in endocrine resistant breast cancer","volume":"130","author":"D. C. Tomlinson","year":"2012","journal-title":"Int. J. Cancer"},{"key":"pone.0231999.ref056","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","article-title":"Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists","volume":"7","author":"W. Toy","year":"2017","journal-title":"Cancer Discov"},{"key":"pone.0231999.ref057","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"J. F. Robertson","year":"2016","journal-title":"The Lancet"},{"key":"pone.0231999.ref058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-015-0075-0","article-title":"KRAS mutant lung cancer: progress thus far on an elusive therapeutic target","volume":"4","author":"S. Bhattacharya","year":"2015","journal-title":"Clin. Transl. Med"},{"key":"pone.0231999.ref059","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"F. Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"pone.0231999.ref060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4614-0899-4_20","article-title":"Notch-signaling and nonmelanoma skin cancer: an ancient friend, revisited","author":"J. Reichrath","year":"2012","journal-title":"Notch Signal. Embryol. Cancer"},{"key":"pone.0231999.ref061","first-page":"689226899","article-title":"Genetic pathways to glioblastoma: a population2based study","volume":"64","author":"H. Ohqaki","year":"2004","journal-title":"Cancer Res"},{"key":"pone.0231999.ref062","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"T. J. Ley","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"pone.0231999.ref063","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"M. J. Walter","year":"2011","journal-title":"Leukemia"},{"key":"pone.0231999.ref064","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"D. P. Steensma","year":"2015","journal-title":"Blood"},{"key":"pone.0231999.ref065","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"C. C. Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"pone.0231999.ref066","article-title":"Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens","author":"E. A. Severson","year":"2018","journal-title":"Blood"},{"key":"pone.0231999.ref067","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-019-0104-z","article-title":"ESR1 mutations in metastatic lobular breast cancer patients","volume":"5","author":"C. Desmedt","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"pone.0231999.ref068","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18632\/aging.101165","article-title":"ESR1 mutations in breast cancer","volume":"9","author":"F. Clatot","year":"2017","journal-title":"Aging"},{"key":"pone.0231999.ref069","unstructured":"A Study of GDC-9545 Alone or in Combination With Palbociclib and\/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer\u2014Full Text View\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03332797. (Accessed: 14th November 2017)"},{"key":"pone.0231999.ref070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13058-017-0851-4","article-title":"Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models","volume":"19","author":"A. Bahreini","year":"2017","journal-title":"Breast Cancer Res"},{"key":"pone.0231999.ref071","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jnci\/90.13.972","article-title":"Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Sauamous Cell Carcinoma","volume":"90","author":"P. P. Leong","year":"1998","journal-title":"J. Natl. Cancer Inst"},{"key":"pone.0231999.ref072","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"G. Genovese","year":"2014","journal-title":"N. Engl. J. Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T11:00:12Z","timestamp":1722855612000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231999"}},"subtitle":[],"editor":[{"given":"Krishna Rani","family":"Kalari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0231999","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]}}}